[Olaparib and pancreatic cancer: A challenging Lesson]

Bull Cancer. 2019 Sep;106(9):715-716. doi: 10.1016/j.bulcan.2019.07.002. Epub 2019 Aug 6.

[Article in French]

Authors

Christophe Louvet¹, Emmanuelle Samalin², Pierre Michel³

Affiliations

¹ Institut mutualiste Montsouris, département d'oncologie médicale, 75014 Paris, France. Electronic address: Christophe.LOUVET@imm.fr.
² Université de Montpellier, institut du cancer de Montpellier-Val d'Aurelle, unité d'oncologie digestive, 34298 Montpellier cedex 5, France.
³ Hôpital universitaire de Rouen, Normandie université, service d'hépato-gastroentérologie, UNIROUEN, Inserm 1245, IRON group, 76000 Rouen, France.

PMID: 31399206
DOI: 10.1016/j.bulcan.2019.07.002

No abstract available

Publication types

Editorial

MeSH terms

Adenocarcinoma / drug therapy*
Adenocarcinoma / genetics
Adenocarcinoma / mortality
Antineoplastic Agents / therapeutic use*
Clinical Trials, Phase III as Topic
Genes, BRCA1
Genes, BRCA2
Germ-Line Mutation
Humans
Pancreatic Neoplasms / drug therapy*
Pancreatic Neoplasms / genetics
Pancreatic Neoplasms / mortality
Phthalazines / therapeutic use*
Piperazines / therapeutic use*
Placebos
Progression-Free Survival
Randomized Controlled Trials as Topic

Substances

Antineoplastic Agents
Phthalazines
Piperazines
Placebos
olaparib